


IMMUNOGEN

ImmunoGen, Inc.
Investor Relations Department
830 Winter Street
Waltham, MA 02451
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: IMGN

| | |
|---------------|---|
| Last Trade: | 6.17 |
| Trade Time: | 4:00 PM ET Oct 19, 2017 |
| Change: | -0.25  (-3.894%) |
| Day Range | 6.08 - 6.47 |
| 52-Week Range | 1.51 - 8.84 |
| Volume | 2,910,616 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roc... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Oct 16, 2017

[ImmunoGen Announces Investigational New Drug Application for IMGN632 for Hematological Malignancies is Active](#)

Oct 11, 2017

[ImmunoGen Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares](#)

Oct 5, 2017

[ImmunoGen Announces Pricing of Public Offering of Common Stock](#)

Oct 4, 2017

[ImmunoGen Announces Proposed Public Offering of Common Stock](#)

Sep 5, 2017

[ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences](#)

Upcoming Events [\[View all \]](#)

Nov 3, 2017 8:00 AM ET

[3rd Quarter 2017 Operating Results Conference Call](#)

Nov 15, 2017 5:40 AM ET

[Jefferies Global Healthcare Conference \(London\)](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Aug 25, 2016

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 4, 2017

[Quarterly Report \(10-Q\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)

Nov 4, 2016

[Quarterly Report \(10-Q\)](#)